INVEST IN THE FUTURE OF PAIN RELIEF
Pain is universal. It disrupts work, time with family, and quality of life. Through innovations, we can make a difference.
Virpax Pharmaceuticals is collaborating with the best minds of the pharmaceutical industry. Working alongside these leaders, we can improve pain management and target pain at its source.
Partner with us as we develop the next generation of pharmaceutical products that can minimize pain and improve people’s lives.
Virpax Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on Epoladerm for the Management of Osteoarthritis of the Knee
505(b)(2) Regulatory Pathway and Proposed Study Design Is Acceptable Virpax to Finalize IND and Prepare for Phase I Human Study Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, today announced that it has successfully completed a [...]
Virpax Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on NES100 for the Management of Acute and Chronic Pain
Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems today announced that it has successfully completed a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA) for NES100 which uses the Nanomerics [...]
Virpax Pharmaceuticals Selected for Two Presentations at the 2020 Special Operations Medical Association Exhibition
Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that their Chief Medical Officer Jeffrey Gudin, M.D., will present two abstracts at the 2020 Special Operations Medical Association’s Training, Education, Scientific Assembly and Exhibition (SOMA) being held May 11-15, 2020, at the [...]